Growth Scale Values Are Gaining Traction in Clinical Trials
Growth scale values (GSVs) have gained traction as a more precise option for measuring outcomes in clinical trials.
Read moreBlog
How do you stay up to date in your field? Our team of experts, authors, and specialists contribute regularly to our profession-specific blogs, keeping you informed of the latest industry trends, news, and innovations. Dive in below and check back often, as new content is added weekly.
-
-
Taking an innovative approach to challenging COA translations
Over the last ten years, the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-3), a leading developmental assessment for children ages 1–42 months, has been referenced as an endpoint in 145 clinical trials (Citeline, 2024). Of those, 6.21% have included sites in the Finno-Ugric countries of Estonia, Finland, and Hungary.
Read more -
Clinical trial considerations: All scores are not created equal
Dr. Lynsey Psimas, Ph.D and Dr. Paul Williams PsyD attended CNS Summit 2023 and were fortunate to have the opportunity to present their poster, Precision Matters: An Analysis on How Various Scores Behave When Measuring Change Over Time; Factors That Inform Score Selection for the Best Results”.
Read more -
An interview with Mark Daniel, author of Growth Scale Value (GSV): Theory, Development, and Applications
In testing and in research, you must have an effective and reliable way to measure change. While raw scores have typically been the go-to for this important role, Growth Scale Values (GSVs) are quickly becoming the preferred method.
Our Director of Pharma Sales, Lynsey Psimas, had the opportunity to speak with Mark Daniel, author of Growth Scale Value (GSV): Theory, Development, and Applications to discuss the importance of GSVs. He spent some time explaining GSVs and their importance in test scoring and pharma research.
Read more
